Příspěvky

Zobrazují se příspěvky z listopad, 2013

60 Years of Data Reveal US Melanoma Epidemic

Survival 81% at 1 Year With MK-3475 in Melanoma

Obrázek
Survival 81% at 1 Year With MK-3475 in Melanoma

There is an overall survival rate of 81% at 1 year in patients with advanced and unresectable melanoma treated with the experimental immunotherapy MK-3475 (Merck), according to a Kaplan–Meier estimate from a phase 1 trial.
Related articlesInterim Data to Be Presented for MK-3475, Merck & Co., Inc.???s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced MelanomaMerck Scores in Investigational Melanoma Study ResultsMerck updates MK-3475 data in MelanomaMerck's immunotherapy cancer treatment drug gets good patient response